ACE2 News and Research

RSS

Dysbiosis in gut microbiota may cause severe secondary infection in COVID-19 patients

An interesting study led by scientists in the U.S. has recently revealed that the microbial community in the gut is directly affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and that virus-mediated gut microbiome dysbiosis may cause severe secondary infections in coronavirus disease 2019 (COVID-19) patients. The study is currently available on the bioRxiv* preprint server.

19 Jul 2021

Stronger and longer SARS-CoV-2 RBD-ACE2 binding associated with glycans in new study

A new study has been published on the bioRxiv* preprint server, which focuses on the mechanism behind the binding of SARS-CoV-2 with the host receptor, using a molecular dynamics approach. The authors of this study aim to highlight the role of glycans in initiating the interaction between S and ACE2.

19 Jul 2021

An assay capable of detecting SARS-CoV-2 antibodies in breast milk and other samples

In a recent study by US researchers (currently available on the medRxiv* preprint server), a specific immunoassay based on the spike glycoprotein’s receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is not only well suited for the detection of antibody response after infection and vaccination but may also represent a method of choice when conducting seroepidemiological studies.

19 Jul 2021

SARS-CoV-2 B.1.617 mutations L452 and E484Q do not work together to evade antibodies

A short report recently published in the Journal of Infectious Diseases demonstrates how spike mutations L452R and E484Q found in the variant B.1.617.1 of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) each confer modestly diminished sensitivity to Pfizer-BioNTech (BNT162b2) mRNA vaccine-elicited antibodies – with combined mutations having a similar impact as either one of them alone.

19 Jul 2021

Evaluation of a synthetic DNA SARS-CoV-2 vaccine INO-4800 using a nonhuman primate model

A new study published in Vaccine assesses the safety and efficacy of the synthetic DNA vaccine candidate INO-4800, delivered as a single or double dose regime.

18 Jul 2021

A drug candidate to prevent adverse reactions due to COVID-19 infection or vaccines

A new study describes the promising results of a new drug candidate in combating the illness caused by the binding of COVID-19-specific antibodies to infected cells.

18 Jul 2021

Mixing COVID vaccines generates a comparable immune response

The validity and safety of mixing first and second doses of different types are explored in a paper recently uploaded to the preprint server medRxiv* by Rose et al. (July 13th, 2021), finding that robust antibody response is induced, comparable to, and perhaps even exceed that generated by homologous dosing.

16 Jul 2021

Short chain fatty acids have potential therapeutic applications against COVID-19, study suggests

SARS-CoV-2, the virus responsible for the COVID-19 pandemic, is highly transmissible, with nasal passages being the target of original infection.

15 Jul 2021

A pencil graphite biosensor that detects SARS-CoV-2

In a new study, scientists discuss the development of a rapid COVID-19 diagnostic tool known as the Low-cost Electrochemical Advanced Diagnostic (LEAD).

14 Jul 2021

New OMV-based COVID-19 vaccine candidate proves effective in mice

Researchers in Italy have demonstrated the efficacy of using modified outer membrane vesicles (OMVs) as a vaccine to protect against coronavirus disease 2019 (COVID-19) in an animal model.

14 Jul 2021

Researchers examine efficacy of CT-P59 monoclonal antibody against SARS-CoV-2 Brazil variant

The therapeutic monoclonal antibody CT-P59 binds to the RBD of SARS-CoV-2, the site of these three major mutations, which may therefore reduce the potency of this antibody against the P.1 lineage. In a new study, the neutralizing potency of this monoclonal antibody towards both wildtype and P.1 SARS-CoV-2 is investigated. The researchers found that the ability to bind with the virus is impeded by the mutations, resulting in reduced potency in vitro.

14 Jul 2021

SARS-CoV-2 variants show distinct humoral response and transcriptional profiles in hamster model

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel, highly infectious respiratory virus, and the causative agent of coronavirus disease 2019 (COVID-19) pandemic. SARS-CoV-2, which first originated in Wuhan, in Hubei province of China, is a member of the Coronavirdae family and has a large, non-segmented RNA genome.

14 Jul 2021

Study identifies SARS-CoV-2 spike conformation exposing potential new therapeutic targets

Researchers in the United States have demonstrated that the viral spike protein used by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to infect host cells adopts an open conformation exposing novel epitopes that could serve as targets for therapeutic strategies to protect against coronavirus disease 2019 (COVID-19).

14 Jul 2021

Molecular dynamic analysis of SARS-CoV-2 inhibitors

A new study reports the results of molecular dynamic simulations that were performed in an effort to identify new drugs that could be effective against SARS-CoV-2.

13 Jul 2021

Neutralizing aptamers block SARS-CoV-2 infection in vitro

A new study describes the clinical utility of aptamers against SARS-CoV-2.

13 Jul 2021

Blood test could be a simple and effective method for monitoring SARS-CoV-2 infection

A blood test that quantifies the protein ACE2, the cellular protein which allows entry of the coronavirus into cells, as well as ACE2 fragments, produced as a result of interaction with the virus, could be a simple and effective method for monitoring SARS-CoV-2 infection, according to a study led by Javier Sáez-Valero, from the UMH-CSIC Neurosciences Institute in Alicante, published in FASEB Journal.

13 Jul 2021

Scientists develop mouse-specific SARS-CoV-2 strains that efficiently replicate in standard laboratory mice

A team of scientists in France recently developed a mouse-adapted strain of SARS-CoV-2 that efficiently replicates in the lungs of standard laboratory mice and induces mild to moderate disease. The study is currently available on the bioRxiv* preprint server.

13 Jul 2021

Review details clinical signs of SARS-CoV-2 infection in domestic and wild cats

Now, a new systematic review has been published in the journal Animals that focuses on the clinical symptoms in felines diagnosed with SARS-CoV-2 worldwide.

13 Jul 2021

Scientists identify novel entry receptors for SARS-CoV-2

Scientists from the Northeastern University, China, and University of Michigan, USA, have recently identified five potential entry receptors for SARS-CoV-2. These receptors specifically express in SARS-CoV-2-infected cells and have a high binding affinity for the viral spike protein.

12 Jul 2021

mRNA-based COVID-19 vaccine CV07050101 demonstrates limited immunogenicity in non-human primates

Scientists from the US and Germany have recently evaluated the efficacy of an mRNA-based COVID-19 vaccine candidate, CV07050101, in inducing humoral and cellular immune responses in non-human primates. The study reveals that prime-boost immunization with the vaccine candidate induces only limited immunity against SARS-CoV-2.

12 Jul 2021

ACE2 News and Research

Dysbiosis in gut microbiota may cause severe secondary infection in COVID-19 patients

Stronger and longer SARS-CoV-2 RBD-ACE2 binding associated with glycans in new study

An assay capable of detecting SARS-CoV-2 antibodies in breast milk and other samples

SARS-CoV-2 B.1.617 mutations L452 and E484Q do not work together to evade antibodies

Evaluation of a synthetic DNA SARS-CoV-2 vaccine INO-4800 using a nonhuman primate model

A drug candidate to prevent adverse reactions due to COVID-19 infection or vaccines

Mixing COVID vaccines generates a comparable immune response

Short chain fatty acids have potential therapeutic applications against COVID-19, study suggests

A pencil graphite biosensor that detects SARS-CoV-2

New OMV-based COVID-19 vaccine candidate proves effective in mice

Researchers examine efficacy of CT-P59 monoclonal antibody against SARS-CoV-2 Brazil variant

SARS-CoV-2 variants show distinct humoral response and transcriptional profiles in hamster model

Study identifies SARS-CoV-2 spike conformation exposing potential new therapeutic targets

Molecular dynamic analysis of SARS-CoV-2 inhibitors

Neutralizing aptamers block SARS-CoV-2 infection in vitro

Blood test could be a simple and effective method for monitoring SARS-CoV-2 infection

Scientists develop mouse-specific SARS-CoV-2 strains that efficiently replicate in standard laboratory mice

Review details clinical signs of SARS-CoV-2 infection in domestic and wild cats

Scientists identify novel entry receptors for SARS-CoV-2

mRNA-based COVID-19 vaccine CV07050101 demonstrates limited immunogenicity in non-human primates

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News